Exploiting UChicago research, Reflexion is eyeing an expansion in Asia after receiving $40m in additional series D funding to bring the round to $150m.
Reflexion, a US-based oncology therapy technology developer partly based on University of Chicago research, secured $40m on Tuesday from healthcare-focused investment firm Ally Bridge Group to expand its series D round to $150m.
The company said it raised $110m of series D funding across 2020, including $100m from investors including Pfizer Ventures and Johnson & Johnson Innovation – JJDC, respective vehicles for pharmaceutical firms Pfizer and Johnson & Johnson, in April 2020.
Canada’s Public Sector Pension Investment Board led the April tranche, which also featured private equity group TPG’s The Rise Fund, KCK Group, Sofinnova Partners, Venrock and T Rowe Price.
Founded in 2009, Reflexion is developing biology-guided radiotherapy technology designed to treat multiple cancer tumours simultaneously. The company is also developing a similar technology that causes tumours to continuously reveal their location in the body.
Todd Powell, president and chief executive of Reflexion, said:…
